Novartis’ Cosentyx® Gains FDA Approval for Patients 12 and Older With Moderate-to-Severe Hidradenitis Suppurativa

Novartis’s Cosentyx gains U.S. Food and Drug Administration approval for patients aged 12+ with moderate-to-severe Hidradenitis Suppurativa. Novartis announced today that Cosentyx® (secukinumab) received US Food and Drug Administration (FDA) approval…

Read MoreNovartis’ Cosentyx® Gains FDA Approval for Patients 12 and Older With Moderate-to-Severe Hidradenitis Suppurativa

Johnson & Johnson Reports Encouraging First-in-Human Results for Erda-iDRS (TAR-210) in Intermediate-Risk Non-Muscle-Invasive Bladder Cancer

Johnson & Johnson Reports Encouraging First-in-Human Data for Erda-iDRS (formerly TAR-210) in Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Johnson & Johnson today announced results from an open-label, multicenter Phase 1 study evaluating…

Read MoreJohnson & Johnson Reports Encouraging First-in-Human Results for Erda-iDRS (TAR-210) in Intermediate-Risk Non-Muscle-Invasive Bladder Cancer

WuXi Biologics Earns Multiple Asia-Pacific Biopharma Excellence Awards for Bioprocessing, Manufacturing, and Digital Innovation Leadership

WuXi Biologics Earns Multiple Asia-Pacific Biopharma Excellence Awards for Advancements in Bioprocessing, Manufacturing Quality, and Digital Innovation WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing…

Read MoreWuXi Biologics Earns Multiple Asia-Pacific Biopharma Excellence Awards for Bioprocessing, Manufacturing, and Digital Innovation Leadership
Celltrion

Celltrion Poised to Gain from Global Biosimilar Regulatory Harmonization, Boosting Scale from Development to Commercialization

Celltrion Poised to Gain from Global Biosimilar Regulatory Harmonization, Enhancing Economies of Scale from Development to Manufacturing and Direct Commercialization Celltrion announced today that it will immediately incorporate newly announced…

Read MoreCelltrion Poised to Gain from Global Biosimilar Regulatory Harmonization, Boosting Scale from Development to Commercialization